Granted Patent
B2
US 12,312,404 · App. 18/448,870 · Granted May 27, 2025
Anti-PVRIG antibodies and methods of use
Inventors:
Mark White (Antioch, CA); Sandeep Kumar (San Bruno, CA); Christopher Chan (South San Francisco, CA); Spencer Liang (San Mateo, CA); Lance Stapleton (Oakland, CA); Andrew W. Drake (Mountain View, CA); Yosi Gozlan (Tel Aviv, IL); Ilan Vaknin (Tel Aviv, IL); Shirley Sameah-Greenwald (Kfar Saba, IL); Liat Dassa (Tel Aviv, IL); Zohar Tiran (Oranit, IL); Gad S. Cojocaru (Tel Aviv, IL); Leonard Presta (San Francisco, CA); Richard Theolis (Santa Cruz, CA)
Assignee:
Compugen Ltd.
C07K16/2803C07K7/06G01N33/57484C07K2317/21C07K2317/33C07K2317/34C07K2317/53C07K2317/55C07K2317/56C07K2317/565C07K2317/70C07K2317/74C07K2317/76C07K2317/92C07K2319/30C07K2319/32C12N15/1138C12N2310/14G01N2333/47
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention is directed to anti-PVRIG antibodies and methods of using same.
Claims (20)
1. A composition comprising an anti-PVRIG antibody, wherein the anti-PVRIG antibody specifically binds to human PVRIG, wherein the antibody comprises a heavy chain and a light chain, and wherein:
a) the heavy chain comprises a heavy chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO: 1434; and
b) the light chain comprises a light chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO:1453.
2. The composition according to claim 1 , wherein the anti-PVRIG antibody specifically binds to human PVRIG with a KD of 10 nM or less.
3. The composition according to claim 1 , wherein the anti-PVRIG antibody activates T-cells and/or NK cells.
4. The composition according to claim 3 , wherein the T cells are cytotoxic T-cells (CTLs).
5. The composition according to claim 3 , wherein the T-cells are CD4+ T-cells or CD8+ T-cells.
6. The composition according to claim 3 , wherein the activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.
7. The composition according to claim 1 , wherein the anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein the hinge region optionally comprises one or more mutations.
8. The composition according to claim 7 , wherein the anti-PVRIG antibody comprises the CL region of human kappa 2 light chain.
9. A composition comprising an anti-PVRIG antibody, wherein the anti-PVRIG antibody specifically binds to human PVRIG, wherein the antibody comprises a heavy chain and a light chain, and wherein:
a) the heavy chain comprises a heavy chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO: 1447; and
b) the light chain comprises a light chain variable domain having at least 90% or at least 95% identity to the amino acid sequence of SEQ ID NO:1462.
10. The composition according to claim 9 , wherein the anti-PVRIG antibody specifically binds to human PVRIG with a K D of 10 nM or less.
11. The composition according to claim 9 , wherein the anti-PVRIG antibody activates T-cells and/or NK cells.
12. The composition according to claim 11 , wherein the T cells are cytotoxic T-cells (CTLs).
13. The composition according to claim 11 , wherein the T-cells are CD4+ T-cells or CD8+ T-cells.
14. The composition according to claim 11 , wherein the activation is measured as an increase in interferon-γ production and/or an increase in cytokine secretion.
15. The composition according to claim 9 , wherein the anti-PVRIG antibody comprises the CH1-hinge-CH2-CH3 region from IgG1, IgG2, IgG3, or IgG4, wherein the hinge region optionally comprises one or more mutations.
16. The composition according to claim 15 , wherein the anti-PVRIG antibody comprises the CL region of human kappa 2 light chain.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 8, 2024
From: WHITE, MARK; KUMAR, SANDEEP; CHAN, CHRISTOPHER; LIANG, SPENCER; STAPLETON, LANCE; DRAKE, ANDREW W.; GOZLAN, YOSI; VAKNIN, ILAN; SAMEAH-GREENWALD, SHIRLEY; DASSA, LIAT; TIRAN, ZOHAR; COJOCARU, GAD S,; PRESTA, LEONARD
To: COMPUGEN LTD.
Reel/Frame 069209/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 8, 2024
From: COMPUGEN USA, INC.
To: COMPUGEN LTD.
Reel/Frame 069209/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 8, 2024
From: WHITE, MARK; KUMAR, SANDEEP; CHAN, CHRISTOPHER; LIANG, SPENCER; STAPLETON, LANCE; DRAKE, ANDREW W.; THEOLIS, RICHARD
To: COMPUGEN USA, INC.
Reel/Frame 069215/0120 →
Continuity (8)
Provisional Application
62235823
· Oct 1, 2015
Provisional Application
62141120
· Mar 31, 2015
Provisional Application
62118208
· Feb 19, 2015
References Cited (163)
US 5661016A
· Lonberg
· 1997
[cited by applicant]
US 6960343B2
· Medzhitov
· 2005
[cited by applicant]
US 7622265B2
· Fan
· 2009
[cited by applicant]
US 8431350B2
· Baldwin et al.
· 2013
[cited by applicant]
US 9499596B2
· Clark et al.
· 2016
[cited by applicant]
US 9695238B2
· Gao et al.
· 2017
[cited by applicant]
US RE46534E
· Baldwin et al.
· 2017
[cited by applicant]
US 20040121370A1
· Baldwin et al.
· 2004
[cited by applicant]
US 20070054360A1
· Gao et al.
· 2007
[cited by applicant]
US 20070243584A1
· West
· 2007
[cited by applicant]
US 20090181024A1
· Baldwin et al.
· 2009
[cited by applicant]
US 20090258013A1
· Clark et al.
· 2009
[cited by applicant]
US 20090318376A1
· Chung
· 2009
[cited by applicant]
US 20110236903A1
· McClellan et al.
· 2011
[cited by applicant]
US 20120082659A1
· Land
· 2012
[cited by applicant]
US 20130302346A1
· Brommage et al.
· 2013
[cited by applicant]
US 20140056890A1
· Gurney et al.
· 2014
[cited by applicant]
US 20140322218A1
· Xiao et al.
· 2014
[cited by applicant]
US 20160152720A1
· Kim et al.
· 2016
[cited by applicant]
US 20160355589A1
· Williams et al.
· 2016
[cited by applicant]
US 20170198042A1
· Williams et al.
· 2017
[cited by applicant]
US 20180344869A1
· Fischer
· 2018
[cited by applicant]
CN 103073644A
· 2013
[cited by applicant]
CN 105492025
· 2016
[cited by applicant]
EP 2067791
· 2009
[cited by applicant]
EP 3021869
· 2014
[cited by applicant]
EP 3183267
· 2015
[cited by applicant]
EP 3208612
· 2017
[cited by applicant]
EP 3295951A1
· 2018
[cited by applicant]
JP 7068275
· 2022
[cited by applicant]
TW 201609813A
· 2016
[cited by applicant]
WO WO1994013804
· 1994
[cited by applicant]
WO WO2000052151
· 2000
[cited by applicant]
WO WO2003023013
· 2003
[cited by applicant]
WO WO2004024068
· 2004
[cited by applicant]
WO WO2004030615
· 2004
[cited by applicant]
WO WO2004058805
· 2004
[cited by applicant]
WO WO2004091658
· 2004
[cited by applicant]
WO WO2005016962
· 2005
[cited by applicant]
WO WO2005019258
· 2005
[cited by applicant]
WO WO2006124667
· 2006
[cited by applicant]
WO WO2007121364
· 2007
[cited by applicant]
WO WO2007124283
· 2007
[cited by applicant]
WO WO2008021290
· 2008
[cited by applicant]
WO WO2009017679
· 2009
[cited by applicant]
WO WO2009126688
· 2009
[cited by applicant]
WO WO2011109637
· 2011
[cited by applicant]
WO WO2012031008
· 2012
[cited by applicant]
WO WO2012129488
· 2012
[cited by applicant]
WO WO2012156515
· 2012
[cited by applicant]
WO WO2012178128
· 2012
[cited by applicant]
WO WO2013184912
· 2013
[cited by applicant]
WO WO2015009856
· 2015
[cited by applicant]
WO WO2015136052
· 2015
[cited by applicant]
WO WO2016011264
· 2016
[cited by applicant]
WO WO2016028656
· 2016
[cited by applicant]
WO WO2016028672
· 2016
[cited by applicant]
WO WO2016073853
· 2016
[cited by applicant]
WO WO2016081423
· 2016
[cited by applicant]
WO WO2016081746
· 2016
[cited by applicant]
WO WO2016081748
· 2016
[cited by applicant]
WO WO2016100882
· 2016
[cited by applicant]
WO WO2016106302
· 2016
[cited by applicant]
WO WO2016134333
· 2016
[cited by applicant]
WO WO2016134335
· 2016
[cited by applicant]
WO WO2016191643
· 2016
[cited by applicant]
WO WO2016196389
· 2016
[cited by applicant]
WO WO2017041004
· 2017
[cited by applicant]
WO WO2017053748
· 2017
[cited by applicant]
WO WO2017059095
· 2017
[cited by applicant]
WO WO2017021526
· 2017
[cited by applicant]
WO WO2018017864A2
· 2018
[cited by applicant]
WO WO2018033798
· 2018
[cited by applicant]
WO WO2018116198A1
· 2018
[cited by applicant]
WO WO2018220446A1
· 2018
[cited by applicant]
WO WO2019157340A1
· 2019
[cited by applicant]
WO WO2021091605A1
· 2021
[cited by applicant]
Alvarez et al., Increased antitumor effects using IL-2 with anti-TGF-β reveals competition between mouse NK and CD8 T cells., J Immunol. Aug. 15, 2014;193(4):1709-16. doi: 10.4049/jimmunol.1400034. Epub Jul. 7, 2014.
[cited by applicant]
Anonymous: “Medimnune to Develop Compugen Imnuno-Oncology Antibodies”, Genetic Engineering and Biotechnology News, n.
[cited by applicant]
Ardolino, M., et al., “DNAM-1 Ligand Expression on Ag-Stimulated T Lymphocytes is Mediated by ROS-Dependent Activation of DNA-Damage Response: Relevance for NK-T Cell Interaction,” Blood, v. 117, No. 18, p. 4778, May 5,…
[cited by applicant]
Bachelet, I., et al., “Mast cell costimulation by CD226 CD112 (DNAM-1 Nectin-2)”, J. of Biol. Chem., v. 281, No. 37, pp. 27190-27196, Sep. 15, 2006.
[cited by applicant]
Bottino, C., et al., “Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule”, J. Exp. Med., v. 198, No. 4, p. 557-567 (Aug. 18, 2003).
[cited by applicant]
Breitling, F., et al., “A surface expression vector for antibody screening”, Gene, 104 (1991) 147-153.
[cited by applicant]
Brinkmann, et al., MABS, v. 9, No. 2, 182-212 (2017).
[cited by applicant]
Brown, et al., “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1”, J. Immunol, Feb. 1, 2003, 170(3): pp. 1257-1266.
[cited by applicant]
Brüggemann, M. et al., “Transgenic animals derived by DNA Microinjection”, Handbook of Therapeutic Antibodies, Second Edition, 2014.
[cited by applicant]
Callahan, M.K., et al., “CTLA-4 and PD-1 pathway blockade combinations in the clinic,” Frontiers in Oncology, v. 4, Art. 385, Jan. 2015.
[cited by applicant]
Carpenter J. F et al., “Rational design of stable lyophilized protein formulations: Some practical advice”, Pharmaceutical Research, vol. 14, No. 8, (Jan. 1, 1997), pp. 969-975.
[cited by applicant]
Certified Copy of US Provisional Application, “Composition and methods for modulating t cell mediated immune response U.S. Appl. No. 62/213,305” Document made available under the PCT in WO 2017/041004 filed Sep. 2, 2016.
[cited by applicant]
Chan, C. J., et al., “Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer,” Current Opinion in Immun. 2012, 24:246-251.
[cited by applicant]
Chen et al., Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J Exp Med (1992) 176 (3): 855-866.
[cited by applicant]
Chen Y et al., “Decreased expression of V-set and immunoglobulin domain containing 1 (VSIGI) is associated with poor prognosis in primary gastric cancer,” J. Surgical Onc., v. 106, No. 3, p. 286-293.
[cited by applicant]
Del Bano, et al., Antibodies, 2016, 5, 1.
[cited by applicant]
Evan, G.I., et al., “Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product”, Mol. Cell. Biol., Dec. 1985, vol. 5, p. 3610-3616.
[cited by applicant]
Fuchs, A., et al., “Cutting Edge: CD96 (Tactile) Promotes Nk Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155)”, J. Immun. 2004; 172:3994-3998; doi: 10.4049/jimmunol.172.7.3994.
[cited by applicant]
Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf.
[cited by applicant]
Gonzales, N.R. et al: “Minimizing the Immunogenicity of Antibodies for Clinical Application”. Tumour Biol. Jan.-Feb. 2005;26(1):31-43.
[cited by applicant]
He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.
[cited by applicant]
Iwai, Yoshiko, et. al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockage,” PNAS v. 99, n. 19, Sep. 17, 2002.
[cited by applicant]
Janda, A., et al., “Ig Constant Region Effects on Variable Region Structure and Function”, Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.
[cited by applicant]
Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.
[cited by applicant]
Joller, N. et al., “Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions,” J. Immunol., 2011; 186:1338-1342; Prepublished online Jan. 3, 2011; doi: 10.4049/jimmunol.1003081.
[cited by applicant]
Jones, P.T., et al., “Replacing the Complementarity-Determining regions in a Human Antibody with Thse from a Mouse,” Nature, v. 321, May 29, 1986.
[cited by applicant]
Kang, J., et al., “Rapid formulation Development for Monoclonal Antibodies,” BioProcess Intl.., 14( )4, Apr. 2016.
[cited by applicant]
Kim et al., Gastric-type expression signature in serrated pathway-associated colorectal tumors., Hum Pathol. May 2015;46(5):643-56. doi: 10.1016/j.humpath.2015.01.003. Epub Jan. 15, 2015.
[cited by applicant]
Kim et al: 11 Extracellular domain of V-set and immunoglobulin domain containing 1 (VSIGI) interacts with sertoli cell membrane protein, while its PDZ-binding motif forms a complex with Z0-1, Molecules and Cells, vol. 3…
[cited by applicant]
Kuehn, H.S., et al., “Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4,” Science, v. 345, issue, 6204, Sep. 26, 2014.
[cited by applicant]
Leach, D. R. et al., “Enhancement of Antitumor Immunity by CTLA4 Blockade”, Science, v. 271, Mar. 22, 1996.
[cited by applicant]
Levy et al., Abstract 581: Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG., Cancer Research, 1 Apr. 1, 2017 (Apr. 1, 2017 ), p. 581, XP055506734.
[cited by applicant]
Liang et al., “Discovery of COM701, a therapeutic antibody targeting the novel imnune checkpoint PVRIG, for the treatment of cancer”, Journal of Clinical Oncology, American Society of Clinical Oncology, US , vol. 35, No…
[cited by applicant]
Lozano, E., et al., “The TIGIT/CD226 Axis Regulates Huan T Cell Function”, J. of Immun., 2012; 188:3869-3875 (2012).
[cited by applicant]
Marks, J.D., et al., “By-passing immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J. Mol. Bio. 222, 581-597 (1991).
[cited by applicant]
Murter, B., et al., “Mouse PVRIG has CD8 T cell specific coinhibitory functions and dampens antitumor immunity,” Cancer Immunology Research, DOI:10.1158/2326-6066.CIR-18-0460, published Jan. 18, 2019.
[cited by applicant]
Nosanchuk, J.D., “The Interdependence of Antibody C and V Regions on Specificity and Affinity: Significant Implications for the Engineering of Therapeutioc Antibodies”, Virulence, v. 4, n. 6, p. 439-440 (Aug. 15, 2013).
[cited by applicant]
Oidovsambuu et al. (2011) Adhesion Protein VSIG1 Is Required for the Proper Differentiation of Glandular Gastric Epithelia. PLoS One 6(10): e25908. doi: 10.1371/journal.pone.0025908.
[cited by applicant]
Ophir et al., “Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Immune Checkpoint PVRIG.”, POS, Jun. 4, 2017 (Jun. 4, 2017), p. 169, XP055506726.
[cited by applicant]
Orentas et al., Bioinformatics description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.
[cited by applicant]
Pauken, K., et al., “TIGIT and CD226 Tipping the Balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit,” Cancer Cell, 26, dx.doi.org/10.1016/j. ccell.2014.11.016.
[cited by applicant]
Pennock et al., “The Evolving Role of Inmune Checkpoint Inhibitors in Cancer Treatment.”, The Oncologist, Jun. 11, 2015 (Jun. 11, 2015), pp. 812-822, XP055320470.
[cited by applicant]
Perez De La Lastra et al., “Epitope Mapping of 10 Monoclonal Antiodies against the Pg Analogue of Human Membrane Cofactor Protein (MCP)”, Immunology, v. 96, n. 4, p. 663-670 (Apr. 1, 1999).
[cited by applicant]
Phan, G.Q., et al., “Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen-4 blockade in patients with metastatic melanoma”, PNAS, v. 100, No. 14, Jul. 8, 2003.
[cited by applicant]
Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.
[cited by applicant]
R&D Systems Catalog, Human VSIGI Antibody, Catalog No. MAB4818, pp. 1-2, Oct. 13, 2015 (Oct. 13, 2015).
[cited by applicant]
Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): p. 135.
[cited by applicant]
Safdari, Y., “Antibody Humanization Methods—A review and Update”, Biotech. and Gen. Eng. Rev., v. 29, n. 2, p. 175-186, 2013.
[cited by applicant]
Scanlan et al : 11 Gl ycoprotein 1-47 A34, a novel t arget for antibody-based cancer inrnunotherapy, Cancer Immunity, Academy of Cancer Immunology, CH, vol. 6, Jan. 1, 2006.
[cited by applicant]
Schaefer, et al., PNAS, v. 108, No. 27, 11187-11192 (2011).
[cited by applicant]
Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.
[cited by applicant]
Shaffer, A. “Novel Immune Checkpoint Identified as Promising Target for Blockade Strategies”, Targeted Oncology, Nov. 1, 2016. Found on Sep. 7, 2021, https://www.targetedonc.com/view/novel-immune-checkpoint-identified-a…
[cited by applicant]
Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.
[cited by applicant]
Tivol, E.A., et al., “Massive Lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4”, Immunity, v. 3, 541-547, 1995.
[cited by applicant]
Tomlinson et al., Methods for generating multivalent and bispecific antibody fragments., Methods Enzymol. 2000:326:461-79. doi: 10.1016/s0076-6879(00)26070-9.
[cited by applicant]
Topalian, S.L., et al., “Safety Activity and Immune Correlates of Anti-PD-1 antibody in cancer,” N. Engl. J. Med. 366; 26, Jun. 28, 2012.
[cited by applicant]
Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.
[cited by applicant]
Walter, G., “Production and Use of Antibodies Against Synthetic Peptides”, J. of Immun. Methods, 88 (1986) 149-161.
[cited by applicant]
Wang W., et al., “Instability, stabilization, and formulation of liquid protein pharmaceuticals”, Intl. J. of Pharm., v 185, No. 2, Aug. 20, 1999 (Aug. 20, 1999), p. 129-188.
[cited by applicant]
Wang, et al., “In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivoi Toxicology in Non-Human Primates”, Cancer Immun. Res., Sep. 1, 204, 2(9): p. 943-856.
[cited by applicant]
Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.
[cited by applicant]
Wilson et al., Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol Genomics. 2006;27(3):201-218. doi:10.115…
[cited by applicant]
Xu, Z, et al., “A Novel Interface Consisting of Homologous Immunoglobulin Superfamily Members with Multiple Functions”, Cellular & Molecular Immun., v. 7, p. 11-19 (2010).
[cited by applicant]
Yoon, S. R., et al., “Understanding of Molecular Mechanisms in Natural Killer Cell Therapy,” Exper. & molec. Med. (2015) 47, e141; doi;10.1038/emm/2014.114.
[cited by applicant]
Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.
[cited by applicant]
Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.
[cited by applicant]